跳至主要内容
临床试验/2024-517107-37-00
2024-517107-37-00已完成1 期

Study to compare drug availability in bloodstream of two oral formulations of mesalazine in healthy volunteers under fed conditions.

Faes Farma S.A.1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年11月11日最近更新:

试验速览

阶段
1 期
状态
已完成
入组人数
60
试验地点
1

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

FAES FARMA Clinical department

Scientific

Faes Farma S.A.

研究点 (1)

Loading locations...

相似试验

已完成
1 期
Comparative Bioavailability of Smartech 2% Sodium Diclofenac Topical Solution and PENNSAID 2% Applied to the Knees of Healthy Male and Female SubjectsOsteoarthritis
ACTRN12622001391763Avance Clinical Pty Ltd32
进行中(未招募)
不适用
Bioavailability, Pharmacokinetics and Pharmacodynamics of Insulin Aspart following Subcutaneous Insulin Infusion (CSII) - Basal Rate Resolution.Type 1 diabetes mellitusContinious subcutaneous insulin infusion (CSII)MedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitus
EUCTR2007-001912-21-DKAarhus Sygehus, Universityhospital of Aarhus
进行中(未招募)
不适用
Bioavailability, Pharmacokinetics and Pharmacodynamics of Insulin Aspart administered in the Duodenum in healthy volunteers – an open single blinded and uncontrolled exploratory trialDiabetes Mellitus
EUCTR2006-002803-15-DKAarhus Sygehus12
进行中(未招募)
1 期
Relative bioavailability and comparative pharmacokinetics (blood levels of the drug) of 13-CRA oral liquid and capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in children requiring treatment cycles of 13-CRA.euroblastomaMedDRA version: 20.0 Level: PT Classification code 10029260 Term: Neuroblastoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10029212 Term: Nervous system neoplasms malignant NEC System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: HLGT Classification code 10029211 Term: Nervous system neoplasms malignant and unspecified NEC System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2016-005104-25-GBova BioPharma Limited20
尚未招募
1 期
Comparative evaluation of the absorption and disposition in the body of a generic formulation of darifenacin 15 mg against the innovator product in healthy fed volunteers.Bioequivalence assessment between two formulations of darifenacin 15 mg.Other - Research that is not of generic health relevance and not applicable to specific health categories listed above
ACTRN12610000894099Center for Clinical Pharmacology Research Bdbeq S.A.24
Study to compare drug availability in bloodstream of... | 临床试验